Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;104(5):e15738.
doi: 10.1111/tan.15738.

Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy

Francisco Javier Gil-Etayo  1   2   3   4 , Jairo Eduardo Niño-Ramírez  1   2   3   4 , Marta Fonseca-Santos  1   2   4 , Daniel Arroyo-Sánchez  1   2   4 , Almudena Navarro-Bailón  1   2   4 , Ariadna Vicente Parra  1   2 , Isabel Jiménez Hernaz  1   2 , Pilar Terradillos Sánchez  1   2 , Francisco Boix  5 , Miguel Alcoceba  1   2   3   4 , Luis Marín  6 , Estefanía Pérez-López  1   2   4 , Mónica Cabrero  1   2   4 , Ana África Martín-López  1   2   4 , Miriam López  1   2   4 , Mónica Baile  1   2   4 , Alejandro Avendaño  1   2   4 , Almudena Cabero  1   2   4 , Ana García-Bacelar  1   2   4 , Lourdes Vázquez  1   2   4   7 , Fermín Sánchez-Guijo  1   2   3   4   7 , Ramón García-Sanz  1   2   3   4   7 , Lucía López-Corral  1   2   3   4   7 , Amalia Tejeda Velarde  1   2   3   4
Affiliations

Quantifying HLA Mismatches at Epitope Level in Haplo-HSCT: Impact in the Outcome in Strategies Using PTCy

Francisco Javier Gil-Etayo et al. HLA. 2024 Nov.

Abstract

Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is one of the most effective therapies for treating malignant haematological disorders. However, HLA disparities are significant barriers to the success of this process since they increase the risk of graft versus host disease (GvHD). HLA disparities quantification could help to anticipate the probability and degree of GvHD, but the best tool for such quantification remains a challenge. The aim of this study was to quantify the degree of HLA epitope incompatibilities using PIRCHE (Predicted Indirectly Recognisable HLA Epitopes) algorithm for immunogenicity prediction and their potential relationship with GvHD degree and clinical outcome. We studied 145 patients who underwent a haplo-HSCT with post-transplant cyclophosphamide (PTCy) from a related donor between 2013 and 2020 at our centre evaluating molecular HLA mismatches by PIRCHE-algorithm. Patients with PIRCHE Score (PS) I + II > 38 in GvH direction, developed acute GvHD grade II-IV earlier than their counterparts (HR: 1.71, 95% CI: 1.02-2.87, p = 0.032). In addition, PS-B > 1 in GvH direction was an independent risk factor for chronic GvHD, (HR: 2.51, 95% CI 1.17-5.36, p = 0.017). A higher incidence of relapse was found for patients with PS-II > 28 HvG (HR: 9.16, 95% CI: 2.47-33.92, p < 0.001) which also favoured a worse GvHD/relapse-free survival in patients with PS-II > 27 in HvG direction (HR: 1.88, 95% CI: 1.11-3.18, p = 0.017). These findings indicate that the alloreactivity inferred by epitope HLA disparities is associated with post-transplant outcomes. Thus, analysing PS could benefit the selection of the most suitable donors allowing patient stratification based on HLA mismatches in the context of haplo-HSCT with PTCy.

Keywords: GRFS; GvHD; HLA; PIRCHE; epitope; haplo‐HSCT.

PubMed Disclaimer

References

    1. J. R. Passweg, H. Baldomero, C. Chabannon, et al., “Hematopoietic Cell Transplantation and Cellular Therapy Survey of the EBMT: Monitoring of Activities and Trends Over 30 Years,” Bone Marrow Transplantation 56, no. 7 (2021): 1651–1664, https://pubmed.ncbi.nlm.nih.gov/33623153/.
    1. M. Park and J. J. Seo, “Role of HLA in Hematopoietic Stem Cell Transplantation,” Bone Marrow Research 2012 (2012): 1–7, https://pubmed.ncbi.nlm.nih.gov/23082252/.
    1. W. Saber, S. Opie, J. D. Rizzo, M. J. Zhang, M. M. Horowitz, and J. Schriber, “Outcomes After Matched Unrelated Donor Versus Identical Sibling Hematopoietic Cell Transplantation in Adults With Acute Myelogenous Leukemia,” Blood 119, no. 17 (2012): 3908–3916, https://pubmed.ncbi.nlm.nih.gov/22327226/.
    1. K. Besse, M. Maiers, D. Confer, and M. Albrecht, “On Modeling Human Leukocyte Antigen‐Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an Unrelated Donor Source,” Biology of Blood and Marrow Transplantation 22, no. 3 (2016): 410–417, https://pubmed.ncbi.nlm.nih.gov/26403513/.
    1. S. R. McCurdy, Y. L. Kasamon, C. G. Kanakry, et al., “Comparable Composite Endpoints After HLA‐Matched and HLA‐Haploidentical Transplantation With Post‐Transplantation Cyclophosphamide,” Haematologica 102, no. 2 (2017): 391–400, https://pubmed.ncbi.nlm.nih.gov/27846611/.

MeSH terms

LinkOut - more resources